Klaricid

Clarithromycin, the active ingredient in Klaricid, is a macrolide antibiotic presented as an oral dosage form for systemic use. It treats a range of bacterial infections, including respiratory, sinus, skin, and gastrointestinal infections, in adult and pediatric patients as prescribed. GNH USA supplies Klaricid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Clarithromycin acts on bacterial infections by inhibiting protein synthesis, making it effective for several common conditions. - Community‑acquired pneumonia: resolves infection and improves respiratory function. - Acute bacterial sinusitis: reduces sinus inflammation and clears pathogenic bacteria. - Skin and soft tissue infections: eradicates causative organisms and promotes healing. - Helicobacter pylori eradication: contributes to combination therapy to eliminate H. pylori infection.

Clarithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, sometimes watery. - Abdominal pain: cramping or discomfort. - Taste disturbance: altered or metallic taste. - Headache: mild to moderate intensity. - Vomiting: occasional episodes.

Serious or Rare Side Effects: - Hepatic dysfunction: elevated liver enzymes or hepatitis. - QT prolongation: risk of cardiac arrhythmias. - Severe allergic reactions: rash, angioedema, anaphylaxis. - Clostridioides difficile‑associated diarrhea: severe colitis. - Arrhythmias: ventricular tachycardia or fibrillation. - Hearing loss: reversible or permanent auditory impairment.

When prescribing Klaricid, consider several safety measures to minimize risk. - Liver function assessment: evaluate hepatic status before initiation. - Cardiac monitoring: observe QT interval in patients with cardiac disease or electrolyte imbalance. - Drug interaction review: check for concurrent CYP3A4 inhibitors or QT‑prolonging agents. - Renal impairment caution: adjust therapy in severe renal dysfunction. - Hypersensitivity avoidance: do not use in patients with known macrolide allergy. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Clarithromycin interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may markedly increase clarithromycin plasma levels. - QT‑prolonging agents (e.g., quinidine, sotalol): heightened risk of torsades de pointes. - Antacids containing aluminum or magnesium: reduce oral absorption of clarithromycin.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring. - Theophylline: increased serum concentrations, risk of toxicity. - Statins (e.g., simvastatin, lovastatin): elevated risk of myopathy or rhabdomyolysis.